Robert A. Somer

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Luc Dirix, István Takács, Guy Jérusalem et al. · Breast Cancer Research and Treatment · 2017 · 739 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant

Neal J. Meropol, Robert A. Somer, John Gutheil et al. · Journal of Clinical Oncology · 2003 · 151 citations

Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format

Lillian Shahied, Yong Tang, R. Katherine Alpaugh et al. · Journal of Biological Chemistry · 2004 · 115 citations · Full text

Cancer Immunosurveillance, Medicine, Immunology +13

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

CH Barcenas, Sara A. Hurvitz, Jack A. Di Palma et al. · Annals of Oncology · 2020 · 102 citations · Full text